Login / Signup

Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.

Amy BodyRachel WongJeremy ShapiroAzim JalaliSue-Anne McLachlanSumitra AnandaLara LiptonPrasad CoorayPeter GibbsBelinda LeeMargaret Lee
Published in: Internal medicine journal (2020)
A substantial proportion of patients with mPDAC still do not receive active treatment, which may in part by explained by age, poor performance status and comorbidity. Gemcitabine-nab-paclitaxel was the preferred first line chemotherapy regimen. Median OS for treated patients in this cohort was comparable to that of recent published clinical trials. This article is protected by copyright. All rights reserved.
Keyphrases